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Summary
Objective: Many studies have evidenced the clinical efficacy of hyaluronan (HA) in the treatment of osteoarthritis (OA). However, human and
animal studies have described proinflammatory effects of HA on cells not involved in OA. We therefore investigated whether different
molecular weight HA preparations can affect proinflammatory cytokine (IL1 and TNF) or chemokine (IL8, MCP-1 and RANTES) expression
in human chondrocytes and synoviocytes isolated from OA patients.
Design: Human chondrocytes and synoviocytes were cultured in vitro in the presence or absence of three different purified HA
pharmaceutical preparations (1×106 Kd, 5×105 Kd and 6.5×104 Kd) and assessed for the production of proinflammatory cytokines and
chemokines and their mRNA expression.
Results: In basal conditions, both chondrocytes and synoviocytes produce only MCP-1 and IL8, along with low quantities of IL1 and TNF,
but not RANTES. IL8 production was generally about 100 times higher in chondrocytes than in synoviocytes, while MCP-1 was roughly twice
as high in synoviocytes than in chondrocytes. At the mRNA level, expression of IL1, TNF, IL8, MCP-1 and RANTES did not change in the
presence of the three HA preparations either in synoviocytes or in chondrocytes with respect to basal condition. None of the three different
HA preparations significantly affected production of IL8 or MCP-1.
Conclusions: These data demonstrate that preparations of HA of the same origin but with different MWs do not induce proinflammatory
cytokines and chemokines expressed by chondrocytes and synoviocytes that are either directly or indirectly involved in OA progression.
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Osteoarthritis (OA) is a degenerative joint disease
characterized by progressive disruption of articular carti-
lage and growth of bone (i.e. osteophytes) at the joint
margins. This is accompanied by varying degrees of infil-
tration of the synovial membrane by mononuclear cells1,2.
The processes that cause progressive cartilage disruption
seem to be related to the production of proinflammatory
cytokines (e.g. IL1, TNF, IL6) which stimulate synthesis
and secretion of collagenases, gelatinases and plasmino-
gen activators by chondrocytes, synoviocytes and mono-
nuclear cells3,4. These proinflammatory cytokines have an
important role not only in the priming but also in the
maintenance of inflammatory processes5. Chemokines too
contribute directly to the modulation of immunocellular
functions. They are not only able to recruit mononuclear
cells in the damaged areas, but also stimulate specific
cellular functions, such as proliferation, production of
degradative enzymes and reactive oxygen radicals6,7. High161production of some chemokines by synovial and cartilage
tissue in rheumatoid arthritis and OA in experimental
models demonstrate an association of specific chemokines
with joint inflammation5,8.
Among the current treatments to relieve OA symptoma-
tology, intraarticular hyaluronan (HA) is clinically effective in
mild OA (grade II–III patients according to radiological
Kellgren–Lawrence scale)9,10. HA helps to slow down
the progression of cartilage lesions11,12. Studies performed
on animals and humans, analysing clinical parameters
and arthroscopic variables commonly used to quantify
chondropathy in OA, have shown that intraarticular injec-
tion of HA is able to slow down the degenerative processes
of OA10–14. Although several studies have proved the
clinical efficacy of HA10,14, the level at which the drug acts
remains unclear. In-vitro studies on therapeutic HA show
that it inhibits cellular chemotaxis of activated macro-
phages and leukocytes15, inhibits phagocytosis induced by
IgG aggregated on neutrophils16 and prostaglandin syn-
thesis17,18, increases proteoglycan synthesis in chondro-
cytes19, modulates the inflammatory responses20,21 and
stimulates synoviocytes’ production of HA22. By contrast,
some studies have revealed that HA may have various
potentially unfavorable effects23–27. Although these studies
do not focus on cells specifically involved in OA, they
suggest a possible role of HA in the regulation of cyto-
kines and chemokines. Recent reports have shown that
low molecular weight (MW) HA preparations can induce
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Primer sequences used for reverse transcriptase-polymer chain reaction
mRNA Primer sequences Fragment size, bp
RANTES 5′-AGGTACCATGAAGGTCTCC-3′ 275
5′-GACTCTCCATCCTAGCTCA-3′
MCP-1 5′-CCAATTCTCAAACTGAAGCTCGCAC-3′ 372
5′-GTTAGCTGCAGATTCTTGGGTTGTG-3′
IL8 5′-ATGACTTCCAAGCTGGCCGTG-3′ 300
5′-TTATGAATTCTCAGCCCTCTTCAAAAACTT-3′
IL1 5′-AAACAGATGAAGTGCTCCTTCAGG-3′ 391
5′-TGGAGAACACCACTTGTTGCTCCA-3′
TNF 5′-CGGGACGTGGAGCTGGCCGAGGAG-3′ 355
5′-CACCAGCTGGTTATCTCTCAGCTC-3′
GAPDH 5′-CTGCCGTCTAGAAAAACC-3′ 219
5′-CCAAATTCGTTCGTTGT CATACC-3′Fig. 1. Immunostaining for collagen type II of isolated human
chondrocytes from an OA patient (no. 1) grown at high density.
Magnification 250×.Fig. 2. Immunostaining for anti-fibroblast (A), anti-CD68 (B), anti-
CD14 (C) of isolated human synoviocytes from an OA patient
(no. 6). Magnification 250×.SPECIMENS
Ten OA patients (mean age: 62 years, mean disease
duration: 75 months, range 12–360) undergoing total hip
replacement provided either an articular cartilage specimenimportant proinflammatory effects. In particular, purified
2×105 Kd HA fragments obtained from human umbilical
cords induced in-vitro activation of human and murine
alveolar macrophages through the up-regulation of MIP1,
MIP1, MCP1 and IL823. Induction of proinflammatory
cytokines and chemokines by HA in animal cells has also
been described in vitro by other authors24–27. Moreover,
HA with low MW up-regulated production of IL1, TNF and
IL8 in human uterine fibroblasts28, and also increased
MCP-1 production in human renal tubular epithelial cells29.
Further investigation is needed to evaluate whether
highly purified preparations of HA can affect the production
of the proinflammatory cytokines that are responsible for
the mechanism of cartilage damage. We therefore
analysed the effects on proinflammatory cytokines and
chemokines expressed by chondrocytes and synovio-
cytes isolated from OA patients of three different levels
of HA: MW (5×105 Kd), routinely used in OA treatment, and
a lower and upper MW (1×106 Kd and 6.5×104 Kd,
respectively).
Osteoarthritis and Cartilage Vol. 9, No. 2 163(five patients, nos. 1–5 in Fig. 3) or synovial tissue (five
patients, nos. 6–10 in Fig. 3). Cartilage specimens were
collected around the maximum diameter of the femoral
head. Nonvascularized tissues that were slightly soft or
fibrillated and white or yellow in color were selected.
Diagnosis of OA was based on clinical, laboratory and
radiologic evaluation30. The 10 OA patients studied showed
grade III–IV radiological features (according to Kellgren
and Lawrence grading system)31. Informed consent was
obtained from the patients as well as the approval of the
hospital’s ethical commitee.CHONDROCYTE ISOLATION
Chondrocytes were isolated from articular cartilage by
sequential enzymatic digestion: 30 min with 0.1% hyaluro-
nidase (Sigma, St Louis, MO, U.S.A.), 1 h with 0.5%
pronase (Sigma) and 1 h with 0.2% collagenase (Sigma) at
37°C in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco BRL, Grand Island, NY, U.S.A.) with 25 mM HEPES
(Sigma), 100 U/ml penicillin (Biological Industries, Israel),
100 g/ml streptomycin (Biological Industries, Kibbutz Beit
Haemek, Israel), 50 g/ml gentamicin (Flow, Biaggio,
Switzerland) and 2.5 g/ml amphotericin B (Gibco BRL).
The isolated chondrocytes were filtered by 100 m and
70 m nylon meshes, washed and centrifuged. The pelletwas then seeded at high density (1.5×105 cells/cm2) and
cultured in DMEM supplemented with 10% fetal calf serum
(FCS) (complete medium) at 37°C in a humidified atmos-
phere of 5% CO2. Cells from the first to third passages
were used for the experiments.
CHONDROCYTE PHENOTYPE ANALYSIS
Immunohistochemical staining using monoclonal anti-
bodies (MoAb) anti-collagen type I and II (both purchased
from Chemicon International Inc, Temecula, CA) were used
to evaluate the stability of the chondrocytic phenotype in
high density cultures. Briefly, 15×104 chondrocytes were
seeded on eight-well chamber slides (Nunc A/S, Roskilde,
Denmark), and after 72 h cells were fixed with 4% PFA for
30 min at room temperature. Cells were incubated with
MoAb anti-human collagen type I (1:100) and type II
(1:100) and sequentially incubated at room temperature
with rabbit anti-mouse Ig (1:25, Dako A/S, Glostrup,
Denmark) and mouse alkaline phosphatase anti-alkaline
phosphatase (APAAP) (1:50, Dako) for 30 min each.
Development was performed using the new fuchsin kit
(Dako).Fig. 3. IL8 and MCP-1 production (pg/ml) of isolated human OA chondrocytes (patients 1–5) and synoviocytes (patients 6–10) in the
presence or absence of HA at three different MWs (1×106, 5×105, 6.5×104 Kd). UN=unstimulated control.ISOLATION OF SYNOVIOCYTES
Human synoviocytes were isolated from synovial tissue
using the procedure of Haubeck et al.32 Briefly, synovial
164 G. Lisignoli et al.: Cytokines unaffected by hyaluronan in OAtissue was dissected from underlying connective tissue and
minced fragments (approximately 1×1 mm) were trans-
ferred to a 25 cm2 tissue culture flask and cultured in 10 ml
of Optimem-1 (Life Technologies Italia Srl, San Giuliano
Milanese, Italy) supplemented with 15% FCS, 50 g/ml of
gentamicin and 2.5 g/ml of amphotericin B (complete
medium). After 7–10 days of culture, tissue fragments were
removed and synovial cells outgrown from the synovial
tissue were mantained in culture. Cells from the third to the
eighth passage were used for the experiments.SYNOVIOCYTE PHENOTYPE ANALYSIS
To assess the relative composition of type A
(macrophage-like) and B (fibroblast-like) synoviocytes,
immunocytochemical staining was performed using MoAb
anti-human fibroblast (1:20; Dako), anti-human CD68
(1:100, Dako) and anti-human CD14 (1:10, Dako). Cells
were incubated for 1 h at room temperature, washed twice
and incubated with labeled polymer hoseradish peroxidase
anti-mouse Moab (HRP Dako Envision Kit) for 30 min at
room temperature. Development was performed using 3,
5-diaminobenzidine (Sigma) as substrate.HA
Highly purified HA from rooster combs was kindly sup-
plied by Fidia (Abano Terme, Padova, Italy) in three differ-
ent MWs: HA-MW 1×106 Kd, HA-MW 5×105 Kd and
HA-MW 6.5x104 Kd. Stock solutions were diluted with PBS
to reach the working concentrations desired.CHONDROCYTE AND SYNOVIOCYTE CULTURE
Preliminary dose-finding and kinetic experiments were
performed to assess the optimal HA concentrations (50,
100 and 200 g/ml) and incubation times (24, 48, and 72 h)
for detecting proinflammatory cytokines and chemokines
(data not shown). In subsequent experiments, we used HA
(of all three MWs) at the concentration of 100 g/ml for
72 h. 15×104 chondrocytes and 4×104 synoviocytes were
seeded in 8-well chamber slides (Nunc A/S) in complete
medium. After 24 h, cells were treated with the three MWs
of HA at a concentration of 100 g/ml, or maintained in
basal conditions as controls. After 72 h, supernatants were
collected and stored at −80°C. Slides were treated with
FCS at room temperature for 5 min and then dried and
stored at −80°C prior to cytokine immunostaining.ANALYSIS OF PROINFLAMMATORY CYTOKINES AND CHEMOKINES
IN SUPERNATANTS
IL1 and TNF were evaluated by ELISA following the
the instructions of the manufacturer (CLB, Amsterdam, The
Netherlands): IL1 (sensitivity >1 pg/ml) and TNF (sensi-
tivity >3 pg/ml). IL8, MCP-1 and RANTES production was
evaluated by specific immunoassays (Pharmingen, San
Diego, CA, USA), standardized in our laboratory and pre-
viously described33. Sensitivity of the assays was >1 pg/ml
for IL8, >5 pg/ml for MCP-1 and >15 pg/ml for RANTES.Fig. 4. Steady-state levels of IL1, TNF, IL8, MCP-1 and
RANTES mRNA in isolated human chondrocytes (patient 3) and
synoviocytes (patient 8). Cells were obtained from two repre-
sentative OA patients and cultured in the presence or absence
of HA at three different MWs (1×106, 5×105, 6.5×104 Kd).
UN=unstimulated control.RNA ISOLATION AND RT-PCR ANALYSIS
Cytokine and chemokine mRNA expression was evalu-
ated on both chondrocytes and synoviocytes after 19 h ofincubation in the presence or absence of the three MWs of
HA. Total RNA was extracted from cell pellets (2-5×105
cells) using the single-step guanidinium thiocyanate-
phenol-chloroform method (RNAzolB, Biotecx Laborato-
ries, Houston, TX). Complementary DNA was synthesized
from 1 g of total RNA per sample with 30 min incubation at
42°C, using Moloney murine leukemia virus reverse tran-
scriptase (Perkin Elmer, Norwalk, CT) in the presence of
oligo-(dT) (Perkin Elmer) according to the manufacturer’s
instructions. Amplification was performed in a Gene Amp
PCR System 9600 thermocycler (Perkin Elmer) for 23–35
cycles of 15 s/95°C denaturation and 30 s/60°C annealing
extension, using recombinant Taq DNA Polimerase (Perkin
Elmer) and the specific primer pairs reported in Table I.
Parallel amplification of cDNA for the housekeeping
enzyme glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an internal control.
To perform semi-quantitative comparison between
samples, serial three-fold dilutions of cDNA (corresponding
to 1.00–1.2 ng of total RNA) were subjected to increasing
PCR cycles (23–26–29–32–35) in order to define the linear
amplification range for each primer set. All cDNA samples
(50 ng equivalent of total RNA) were then amplified at the
optimal cycle number for each gene of interest (35 cycles
for IL1 and TNF, 32 cycles for RANTES and IL8, 30
cycles for MCP1 and for the housekeeping gene GAPDH,
23 cycles). The resulting bands were visualized on a 2%
agarose gel stained with ethidium bromide and compared
with a 123 bp DNA ladder (Life Technologies Ltd) to confirm
the predicted size. Relative levels of PCR products were
quantified by densitometric analysis of gel photographs
using a desktop scanner and an image analysis system
(Molecular Analyst, Bio-Rad). Results were expressed as
a percentage of the signal obtained from a parallel
amplification for GAPDH in the same RT product.
Osteoarthritis and Cartilage Vol. 9, No. 2 165STATISTICAL ANALYSIS
Non-parametric ANOVA and Mann–Whitney U-test
were utilized to compare the variables between groups.
Wilcoxon test was applied to analyse paired data. CSS
Statistica statistical software (Statsoft Inc, Tulsa, U.K.) was
used for analysis.ResultsANALYSIS OF CELL PHENOTYPES
Chondrocyte and synoviocyte phenotypes were immu-
nohistochemically assessed. The chondrocytes obtained
from all five patients analysed (nos. 1–5) were positive for
collagen II (Fig. 1) and negative for collagen I, clearly
indicating that the chondrocyte phenotype was maintained
under the culture conditions. The synoviocytes obtained
from the five patients analysed (nos. 6–10) were mainly
positive to anti-fibroblast MoAb (90%) and only slightly
positive to macrophage-like cells markers, anti-CD68 (8%)
and anti-CD14 (2%), indicating a fibroblast phenotype
(Fig. 2).EFFECT OF HA ON PROINFLAMMATORY CYTOKINE PRODUCTION
Proinflammatory cytokine IL1 and TNF were
measured in the supernatant of chondrocytes (patients
1–5) and synoviocytes (patients 6–10) cultured for 72 h in
the presence or absence of HA of three different MWs. Only
very low or undetectable levels (patients 1, 2, 4 and 6, 7, 9
respectively) of both IL1 and TNF were present in basal
conditions or after the addition of the various MWs of HA.
Immunohistochemical staining for IL1 and TNF was also
performed on the cells from which the supernatant had
been collected. Cells were positive to IL1 and TNF and
no differences were observed either in the presence or
absence of different HA preparations (data not shown).Fig. 5. Graphic representations of steady-state cytokine mRNA levels in isolated human OA chondrocytes (patients 1–3) and synoviocytes
(patients 6–8) in the presence or absence of HA at three different MWs (1×106, 5×105, 6.5×104 Kd). IL1 and TNF mRNAs were detected
using RT-PCR and were normalized by GAPDH expression.EFFECT OF HA PREPARATIONS ON CHEMOKINE PRODUCTION
Chondrocytes (patients 1–5) and synoviocytes (patients
6–10) were cultured for 72 h in the presence or absence of
HA. Isolated chondrocytes and synoviocytes constitutively
produced IL8 and MCP-1, but not RANTES (Fig. 3). Inter-
estingly, IL8 production was generally about 100 times
higher in chondrocytes than in synoviocytes, while MCP-1
166 G. Lisignoli et al.: Cytokines unaffected by hyaluronan in OAwas roughly twice as high in synoviocytes than in chondro-
cytes. As shown in Fig. 3, the production of IL8 and MCP-1
by chondrocytes and synoviocytes was not affected by HA
preparations at any of the three MWs; RANTES production
was never detectable.EFFECT OF HA PREPARATIONS ON CYTOKINE AND CHEMOKINE
MRNA EXPRESSION
Semi-quantitative RT-PCR was performed to evaluate
cytokine and chemokine expression at the mRNA level. A
total of six different cases of OA were analysed for IL1,
TNF, IL8, MCP-1 and RANTES mRNA in chondrocytes(patients 1–3) and synoviocytes (patients 6–8). PCR
products for all the genes of interest were clearly detected
in RNA preparations from all samples (Fig. 4). Semi-
quantitative analysis confirmed that mRNA espression
was not modulated in either cell type by any of the HA
preparations (Figs 5 and 6).Fig. 6. Graphic representations of steady-state chemokine mRNA levels in isolated human OA chondrocytes (patients 1–3) and synoviocytes
(patients 6–8) in the presence or absence of HA at three different MWs (1×106, 5×105, 6.5×104 Kd). IL8, MCP-1 and RANTES mRNAs were
detected using RT-PCR and were normalized by GAPDH expression.Discussion
The present study demonstrates that different HA
preparations do not induce proinflammatory cytokines
and chemokines expressed by chondrocytes and synovio-
cytes that are either directly or indirectly involved in OA
Osteoarthritis and Cartilage Vol. 9, No. 2 167progression. Intraarticular injection of HA is extensively
used in clinical practice to relieve the pain and functional
disability caused by the progressive alteration of osteo-
arthritic cartilage, bone and synovia. Data on the specific
effects of HA on the major target cells of OA (i.e. chondro-
cytes and synoviocytes) could expand our knowledge of
the therapeutic action of this drug. Various studies have
demonstrated that HA injections reduce PGE2 synthesis,
increase cAMP levels and influence some important
inflammatory mediators34–35, but few data are available on
OA chondrocytes and synoviocytes. In particular, little is
known about the role of different sized HA preparations
on the expression of the proinflammatory cytokines and
chemokines that are either directly or indirectly involved in
cartilage damage.
In the present study, we analysed the expression of the
proinflammatory factors IL1, TNF, RANTES, IL8 and
MCP-1 in isolated human chondrocytes and synovial cells
in both basal and HA-treated conditions. Because in animal
models MW seems to constitute an important parameter for
the efficacy of OA treatment36,37, we focused our attention
on three different HA preparations (of 1×106 Kd, 5×105 Kd,
and 6.5×104 Kd). In basal conditions, both chondrocytes
and synoviocytes produce only MCP-1 and IL8, along with
low quantities of IL1 and TNF, but not RANTES38–40. We
found that none of the three different sizes of HA tested
affected any of these factors. These findings demonstrate
that, even at a MW as low as 6.5×105 Kd, HA does not
affect proinflammatory cytokine production and expression.
Since the MW of HA is reduced in the synovial fluid of OA
patients as compared with normal subjects41, we can
hypothesize that the fragmented HA usually present in OA
fluid is not implicated in cytokine up-regulation.
Analysing the effect of different sized HA on chemokines
in human alveolar macrophages in vitro, McKee et al.23
found that small HA fragments up-regulate IL8 production,
while in a murine alveolar macrophage cell line they pro-
vided evidence of HA-induced RANTES gene expression
and increased secretion of MIP1, MIP1 and MCP1.
Kobayashi et al.28 came to similar conclusions about
fibroblasts. By contrast, our study indicates that in synovial
cells [which include both the macrophage-like (CD68+)
type A synoviocytes and the fibroblast-like type B synovio-
cytes] chemokine production is not affected by HA. This
finding is consistent with the concept that synovial macro-
phages and fibroblasts are committed cells that display
specific biological responses to the endogenous molecules
found in the extracellular matrix, like HA.
In OA chondrocytes, we did not observe any induction of
the proinflammatory factors analysed. With regard to
cytokine expression by OA chondrocytes, the present study
revealed very low cytokine production in cell surnatants but
a moderate expression at the mRNA level. These findings
are in line with the results of Melchiorri et al.42, who
observed diffuse IL1 and TNF immunostaining in the
human OA chondrocytes. Interestingly, Takahashi et al.20
found that in an animal OA model (ACLT transection), HA
(at a MW of 8×105 Kd) can inhibit IL1 expression in
synovium in the early stages of OA, but that in advanced
OA it exerts no effect on IL1 expression in either synovio-
cytes or chondrocytes. This observation is in line with our
findings on IL1 expression in grade III OA chondrocytes.
It is possible that any variations in the effects exerted by
HA in different grades of OA could depend on the differ-
ent capacities of surface receptors (especially CD44) to
constitutively bind HA, rather than on the MW of the HA.As regards the question of the possible influence of MW,
we investigated whether this factor could constitute a
relevant parameter in the biological action of HA. Although
major differences have been found in animals in the
pharmacological properties of HA of high and low MW36,
our results suggest that MW does not significantly affect the
biological action of HA on human chondrocytes and syn-
oviocytes. We thus conclude that, independently of their
MW, HA preparations tested do not induce the main pro-
inflammatory factors that are directly or indirectly involved
in OA progression.Acknowledgments
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